Bausch + Lomb Announces Statistically Significant Topline Results from Second Phase 3 Trial of NOV03

Bausch + Lomb and Novaliq announced statistically significant topline data from the second Phase 3 (MOJAVE) trial evaluating the investigational...

Read More

Bausch + Lomb Announces Results from First Phase 3 Trial of NOV03

Bausch + Lomb and Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics, announced statistically significant...

Read More